Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

MilliporeSigma has about 1,700 employees in Wisconsin at facilities in Milwaukee, Port Washington, Sheboygan and in the ...

The pharmaceutical company posted revenue of $16.66 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $16.55 billion. Merck expects full-year earnings in ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

A key panel of U.S. health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and Merck & Co. that protect against pneumococcal disease, clearing a path ...

Merck will face an important patent cliff by the end of the decade. The company has a plan to move beyond it. Competition from a new therapy shouldn't derail Merck's prospects. Even when we zoom ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Merck MRK will report its third-quarter earnings on Oct. 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.54 billion and $1.54 per share, respectively.

In June this year, the FDA approved Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.